natgillin/translations-raw huggingface dataset:
In a study of adult patients undergoing pharmacological stress radionuclide MPI with Rapiscan, randomized to placebo (n=66) or caffeine (200 mg, n=70 or 400 mg, n=71) administered 90 minutes before the test, caffeine compromised the diagnostic accuracy of detecting reversible perfusion defects (p<0.001).
U ispitivanju na odraslim bolesnicima koji će se podvrgnuti farmakološkom stresu primjenom Rapiscana radi MPI pomoću radionuklida, u kojem su ispitanici randomizirani u skupinu koja prima placebo (n=66) ili skupinu koja prima kofein (200 mg, n=70 ili 400 mg, n=71) 90 minuta prije testiranja, kofein je kompromitirao dijagnostičku preciznost utvrđivanja reverzibilnih defekata perfuzije (p<0,001).
In a study of brinzolamide in subjects with renal impairment, a 1.6- to 2.8-fold increase in the systemic exposure to brinzolamide and N-desethylbrinzolamide between normal and moderately renally-impaired subjects was demonstrated.
Ispitivanje brinzolamida u ispitanika s oštećenom bubrežnom funkcijom pokazalo je da je sistemska izloženost brinzolamidu i N-desetilbrinzolamidu u ispitanika s umjereno oštećenom bubrežnom funkcijom bila 1,6-2,8 puta veća nego u onih s urednom bubrežnom funkcijom.
In a study of fertility and early embryonic development in mice, fesoterodine had no effect on male or female fertility at the highest dose evaluated, 45 mg/kg/day.
U ispitivanju utjecaja na plodnost i rani embrionalni razvoj u miša, fesoterodin nije imao učinka na plodnost mužjaka i ženki pri najvišoj ispitanoj dozi od 45 mg/kg na dan.
In a study of fertility, in male rats dosed for 70days prior to mating, testicular and epididymal weights and percent motile sperm were decreased at 60 mg/kg, approximately equal to the maximum clinical dose of 800 mg/day, based on body surface area.
U ispitivanju fertilnosti, u mužjaka štakora koji su primali dozu tijekom 70 dana prije parenja, smanjila se težina testisa i epididimisa te postotak pokretljive sperme uz dozu od 60 mg/kg, što je približno jednako maksimalnoj kliničkoj dozi od 800 mg/dan, temeljeno na veličini površine tijela.
In a study of healthy volunteers oral sildenafil at steady state (80 mg three times a day) resulted in a 50 % increase in bosentan AUC (125 mg twice daily).
U ispitivanju provedenom sa zdravim dobrovoljcima sildenafil je u stanju dinamičke ravnoteže (80 mg tri puta na dan) povećao AUC bosentana (125 mg dva puta na dan) za 50%.
In a study of healthy volunteers, symptoms of flushing, dizziness and increased heart rate were assessed as intolerable at regadenoson doses greater than 0.02 mg/kg.
U ispitivanju provedenom na zdravim dragovoljcima, simptomi crvenila s osjećajem vrućine, omaglice i povećane frekvencije srca ocijenjeni su kao nepodnošljivi pri dozama regadenosona većim od 0,02 mg/kg.
In a study of HIV infected intravenous drug users, co-administration of efavirenz with methadone resulted in decreased plasma levels of methadone and signs of opiate withdrawal.
U ispitivanju intravenskih ovisnika zaraženih HIV–om istodobna primjena efavirenza i metadona dovela je do sniženja koncentracije metadona u plazmi i znakova ustezanja od opijata.
In a study of HIV infected intravenous drug users, co-administration of efavirenz with methadone resulted in decreased plasma levels of methadone and signs of opiate withdrawal.
U istraživanju s intravenskim ovisnicima o drogama inficiranima virusom HIV-a istovremena primjena efavirenza i metadona dovela je do smanjenja razine metadona u plazmi i znakova apstinencije od opijata.
In a study of one breastfeeding mother with Parkinson’s disease, excretion of levodopa in human milk was reported.
U ispitivanju jedne majke dojilje koja ima Parkinsonovu bolest, prijavljeno je izlučivanje levodope u majčino mlijeko.
In a study of platinum-resistant recurrent ovarian cancer patients, alopecia, mucosal inflammation, peripheral sensory neuropathy, proteinuria and hypertension were also reported and occurred at a rate at least 5% higher in the CTBV arm for bevacizumab-treated patients  65 years of age compared with bevacizumab-treated patients aged < 65 years.
U ispitivanju recidiva karcinoma jajnika rezistentnog na platinu prijavljene su i alopecija, upala sluznice, periferna senzorna neuropatija, proteinurija i hipertenzija, a stopa njihova pojavljivanja u skupini koja je primala kemoterapiju i bevacizumab bila je najmanje 5% veća u bolesnica liječenih bevacizumabom u dobi od ≥ 65 godina nego u bolesnica liječenih bevacizumabom u dobi od ≤ 65 godina.
In a study of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, raloxifene did not affect the incidence of myocardial infarction, hospitalized acute coronary syndrome, overall mortality, including overall cardiovascular mortality, or stroke, compared to placebo.
U ispitivanju žena u postmenopauzi s dokazanom koronarnom bolesti srca ili povećanim rizikom od koronarnih događaja, raloksifen u usporedbi s placebom nije utjecao na incidenciju infarkta miokarda, hospitalizacije zbog akutnog koronarnog sindroma, ukupnu smrtnost uključujući ukupnu srčano- krvožilnu smrtnost ili moždani udar.
In a study of pregnant rats receiving a combination of lidocaine and prilocaine during organogenesis, no effects on embryonic/foetal development were observed.
U studiji provedenoj na trudnim štakoricama koje su primale kombinaciju lidokaina i prilokaina u razdoblju organogeneze nisu uočeni nikakvi učinci na embrionalni/fetalni razvoj.
In a study of prevention of stroke and SEE in adult patients with NVAF, dabigatran etexilate was associated with higher rates of major gastrointestinal (GI) bleeding which was statistically significant for dabigatran etexilate 150 mg twice daily.
U studiji prevencije moždanog udara i SE-a na odraslim bolesnicima s NVAF-om, dabigatran je povezan s višom stopom velikog gastrointestinalnog (GI) krvarenja, statistički značajno za dozu od 150 mg dvaput dnevno.
In a study of ReFacto in children less than 6 years of age, pharmacokinetic analysis revealed half-life and recovery less than that observed in older children and adults (see section 5.2).
U ispitivanju ReFacto u djece u dobi manjoj od 6 godina, farmakokinetička analiza otkrila je su poluvijek i povrat manji od onih opaženih u starije djece i odraslih (vidjeti dio 5.2).
In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline.
U ispitivanju hemodinamičkih učinaka jedne peroralne doze od 100 mg sildenafila u 14 bolesnika s teškom bolešću koronarnih arterija (stenoza > 70% u barem jednoj koronarnoj arteriji), srednja vrijednost sistoličkog krvnog tlaka u mirovanju snižen je za 7%, a dijastoličkog za 6% u odnosu na početne vrijednosti.
In a study of toxicity to reproduction and development in rabbits, an increased incidence of post-implantation loss and abortion has been observed at high doses of lipegfilgrastim, likely owing to an exaggerated pharmacodynamic effect specific for rabbits.
U ispitivanju toksičnosti za reprodukciju i razvoj na kunićima, povećana incidencija gubitaka nakon implantacije i pobačaja opažena je pri visokim dozama lipegfilgrastima, najvjerojatnije zbog prejakog farmakodinamičkog učinka specifičnog za kuniće.
In a study of uninfected volunteers, a representative nervous system symptom had a median time to onset of 1 hour post-dose and a median duration of 3 hours.
U ispitivanju nezaraženih dobrovoljaca tipični simptomi živčanog sustava javljali su se s medijanom vremena pojave od 1 sat nakon uzimanja lijeka, te s medijanom trajanja od 3 sata.
In a study on male and female fertility in rats no effects were seen (see section 5.3).
U ispitivanjima na mušku i žensku plodnost štakora, nisu uočeni učinci (vidjeti dio 5.3).
In a study on male and female fertility in rats no effects were seen (see section 5.3).
U ispitivanju plodnosti mužjaka i ženki provedenom na štakorima nisu uočeni nikakvi učinci (vidjeti dio 5.3).
In a study on pre- and postnatal development the survival rate of offspring was significantly reduced at doses which slightly reduced maternal weight.
U ispitivanju prenatalnog i postnatalnog razvoja, stopa preživljenja mladunaca znatno se smanjila pri dozama koje su malo smanjile majčinu težinu.
In a study performed in healthy volunteers, netupitant does not affect the exposure of digoxin, a P-gp substrate, whereas it increases its Cmax by fold [90%CI 0.9-1.31].
Prema ispitivanju provedenom u zdravih dobrovoljaca, netupitant ne utječe na izloženost digoksinu, supstratu P-gp-a, ali povećava njegov Cmax za 1,09 puta [90% CI 0,9-1,31].
In a study performed in patients with renal impairment, the most common adverse reactions reported over all cycles across all cohorts were diarrhoea (57.6%), nausea (42.4%), vomiting (36.4%), fatigue (33.3%) and anaemia (24.2%).
U studiji provedenoj na bolesnicima s oštećenjem bubrega najčešće zabilježene nuspojave tijekom svih ciklusa kroz sve kohorte bile su proljev (57,6 %), mučnina (42,4 %), povraćanje (36,4 %), umor (33,3 %) i anemija (24,2 %).
In a study performed in patients with severe hepatic impairment (Child- Pugh score 10-12) (n=8), lower plasma concentrations of micafungin and higher plasma concentrations of the hydroxide metabolite (M-5) were seen compared to healthy subjects (n=8).
U ispitivanju provedenom u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh bodovi: 10-12) (n = 8), opažene su niže koncentracije mikafungina u plazmi i više koncentracije hidroksi-metabolita (M-5) u plazmi u usporedbi s onima u zdravih ispitanika (n = 8).
In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).
U ispitivanju koje je bilo odraz kliničke prakse bilo je moguće prekinuti istodobno antiepileptičko liječenje u ograničenog broja bolesnika koji su odgovorili na dodatno liječenje levetiracetamom (36 od 69 odraslih bolesnika).
In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).
U studiji, koja je bila odraz kliničke prakse, bilo je moguće prekinuti istodobno antiepileptičko liječenje u ograničenog broja bolesnika koji su odgovorili na dodatno liječenje levetiracetamom (36 od 69 odraslih bolesnika).
In a study to assess the effects of tadalafil on vision, no impairment of colour discrimination (blue/green) was detected using the Farnsworth Munsell 100 hue test.
U ispitivanju u kojemu su se ocjenjivali učinci tadalafila na vid primjenom Farnsworth-Munsellovog testa 100 nijansi nije otkriven poremećaj razlikovanja boja (plava/zelena).
In a study using orally administered 14C-memantine, a mean of 84 % of the dose was recovered within 20 days, more than 99 % being excreted renally.
U ispitivanju u kojem je korišten peroralno primijenjen 14C-memantin, uklonjeno je prosječno 84% doze unutar 20 dana, više od 99% izlučeno je putem bubrega.
In a study using orally administered 14C-memantine, a mean of 84 % of the dose was recovered within 20days, more than 99 % being excreted renally.
U ispitivanju u kojem je korišten oralno primijenjen 14C-memantin uklonjeno je prosječno 84% doze unutar 20 dana, a više od 99% izlučeno je putem bubrega.
In a study using orally administered 14C-memantine, a mean of 84% of the dose was recovered within 20 days, more than 99% being excreted renally.
U ispitivanju u kojem je korišten oralno primijenjen 14C-memantin uklonjeno je prosječno 84% doze unutar 20 dana, a više od 99% izlučeno je putem bubrega.
In a study using orally administered 14C-memantine, a mean of 84% of the dose was recovered within20 days, more than 99% being excreted renally.
U ispitivanju u kojem je korišten oralno primijenjen 14C-memantin, uklonjeno je prosječno 84% doze unutar 20 dana, više od 99% izlučeno je putem bubrega.
In a study with intravenous infusion of iloprost, patients with end-stage renal failure undergoing intermittent dialysis treatment are shown to have a significantly lower clearance (mean CL = 5 ± 2 ml/minute/kg) than that observed in patients with renal failure not undergoing intermittent dialysis treatment (mean CL = 18 ± 2 ml/minute/kg).
U ispitivanju s intravenskom infuzijom iloprosta u bolesnika sa zatajenjem bubrega u završnoj fazi na intermitentnoj dijalizi uočen je značajno niži klirens (srednja vrijednost CL = 5 ± 2 ml/minuta/kg) od onog koji je uočen u bolesnika sa zatajenjem bubrega koji se ne podvrgavaju intermitentnoj dijalizi (srednja vrijednost CL = 18 ± 2 ml/minuta/kg).
In a study with oral immediate release 14C-paliperidone, one week following administration of a single oral dose of 1 mg immediate release 14C-paliperidone, 59% of the dose was excreted unchanged into urine, indicating that paliperidone is not extensively metabolised in the liver.
U ispitivanju s oralnim 14C-paliperidonom s trenutnim oslobađanjem, tjedan dana nakon primjene jednokratne peroralne doze od 1 mg 14C-paliperidona s trenutnim oslobađanjem, 59% doze izlučeno je u urinu u nepromijenjenom obliku, što upućuje na činjenicu da se paliperidon u jetri ne metabolizira u velikoj mjeri.
In a study with oral paliperidone in subjects with moderate hepatic impairment (Child-Pugh class B), the plasma concentrations of free paliperidone were similar to those of healthy subjects.
U ispitivanju oralnog paliperidona u osoba s umjerenim oštećenjem jetrene funkcije (Child- Pugh stadij B), plazmatske koncentracije slobodnog paliperidona bile su slične kao u zdravih osoba.
In a study with the seasonal trivalent live attenuated influenza vaccine (T/LAIV), an increased incidence of medically significant wheezing was seen in children 12-23 months of age (see section 4.8).
U ispitivanju sezonskog trovalentnog živog atenuiranog cjepiva protiv influence (T/LAIV) u djece u dobi od 12 do 23 mjeseca zamijećena je povišena incidencija klinički značajnog piskanja (vidjeti dio 4.8).
In a study, including 1,662 children, fever of  38 °C was reported in 41.2 % of children who received Prevenar simultaneously with DTP as compared to 27.9 % in the control group.
U jednom ispitivanju, koje je uključilo 1662 djece, zabilježena je vrućica od 38°C u 41,2% djece koja su primila Prevenar istovremeno s DTP-om u usporedbi s 27,9% u kontrolnoj skupini.
In a sub-study in 13 male alemtuzumab-treated patients (treated with either 12 mg or 24 mg), there was no evidence of aspermia, azoospermia, consistently depressed sperm count, motility disorders or an increase in sperm morphological abnormalities.
U podispitivanju, u kojem je sudjelovalo 13 bolesnika muškoga spola liječenih alemtuzumabom (u dozama od 12 mg ili 24 mg), nisu pronađeni dokazi aspermije, azoospermije, stalno smanjenog broja spermija, poremećaja pokretljivosti niti povećanja morfoloških anomalija spermija.
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to
U analizi podskupina sačinjenih prema stanju (infarkt miokarda, ishemijski moždani udar, BPA) najveću su korist od liječenja (postignuta statistička značajnost pri p = 0,003) imali bolesnici s bolešću perifernih arterija (BPA), posebno oni koji su u anamnezi imali infarkt miokarda (RRR = 23,7%; CI: 8,9 do 36,2), a manja korist (ne značajno različita od učinka ASK) uočena je u bolesnika s moždanim udarom (RRR = 7,3%; CI: -5,7 do 18,7 [p = 0,258]).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p = 0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to
U analizi podskupina sačinjenih prema stanju (infarkt miokarda, ishemijski moždani udar, BPA) najveću su korist od liječenja (postignuta statistička značajnost pri p = 0,003) imali bolesnici s bolešću perifernih arterija (BPA), posebno oni koji su u anamnezi imali infarkt miokarda (RRR = 23,7%; CI: 8,9 do 36,2), a manja korist (ne značajno različita od učinka ASK) uočena je u bolesnika s moždanim udarom (RRR = 7,3%; CI: -5,7 do 18,7 [p=0,258]).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR = 23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR = 7.3%; CI: -5.7 to
U analizi podskupina sačinjenih prema stanju (infarkt miokarda, ishemijski moždani udar, BPA) najveću su korist od liječenja (postignuta statistička značajnost pri p = 0,003) imali bolesnici s bolešću perifernih arterija (BPA), posebno oni koji su u anamnezi imali infarkt miokarda (RRR = 23,7%; CI: 8,9 do 36,2), a manja korist (ne značajno različita od učinka ASK) uočena je u bolesnika s moždanim udarom (RRR = 7,3%; CI: -5,7 do 18,7 [p=0,258]).
In a subgroup analysis by qualifying condition (myocardial infarction, ischaemic stroke, and PAD) the benefit appeared to be strongest (achieving statistical significance at p=0.003) in patients enrolled due to PAD (especially those who also had a history of myocardial infarction) (RRR=23.7%; CI: 8.9 to 36.2) and weaker (not significantly different from ASA) in stroke patients (RRR=7.3%; CI: -5.7 to
U analizi podskupina sačinjenih prema stanju (infarkt miokarda, ishemijski moždani udar, PAD) najveću su korist od liječenja (postignuta statistička značajnost pri p = 0,003) imali bolesnici s bolešću perifernih arterija (BPA), posebno oni koji su u anamnezi imali infarkt miokarda (RRR = 23,7%; CI: 8,9 do 36,2), a manja korist (ne značajno različita od učinka ASK) uočena je u bolesnika s moždanim udarom (RRR = 7,3%; CI: -5,7 do 18,7 [p=0,258]).
In a subgroup analysis in patients 6 to 11 years of age (8 patients on placebo and 9 patients on ivacaftor), the placebo group showed an improvement in mean percent predicted FEV1 from 94.0% at baseline to 98.4% post-baseline; the ivacaftor group showed a slight decline in mean FEV1 from 97.5% at baseline to 96.2% overall post-baseline.
U analizi podskupine bolesnika u dobi od 6 do 11 godina (8 bolesnika koji su primali placebo i 9 bolesnika koji su primali ivakaftor), skupina koja je primala placebo pokazala je poboljšanje prosječnog postotka predviđenog FEV1 od 94,0% na početku do 98,4% nakon početka; skupina koja je primala ivakaftor pokazala je blago sniženje prosječnog FEV1 od 97,5% na početku do ukupno 96,2% nakon početka.
In a subgroup analysis in patients with a confirmed R117H-5T genetic variant, the difference in the mean absolute change from baseline through week 24 in percent predicted FEV1 between ivacaftor and placebo was 5.3% (95% CI 1.3, 9.3).
U analizi podskupine bolesnika s potvrđenom genetskom varijantom R117H-5T, razlika u prosječnoj apsolutnoj promjeni od početka do 24. tjedna u postotku predviđenog FEV1 između ivakaftora i placeba iznosila je 5,3% (95% CI 1,3; 9,3).
In a subgroup of 6 subjects, idarucizumab was administered a second time, two months after the first administration.
U podskupini od 6 ispitanika, idarucizumab je primijenjen drugi put, dva mjeseca nakon prve primjene.
In a subgroup of subjects enrolled in this study (10 Respreeza-treated subjects) bronco-alveolar lavage have been performed.
U podskupini ispitanika uključenih u ovo ispitivanje (10 ispitanika liječenih Respreezom) učinjena je bronhoalveolarna lavaža.
In a subsequent open-label study (SP824), a multicenter, multinational study, the tolerability of overnight switching from ropinirole, pramipexole or cabergoline to rotigotine transdermal patch and its effect on symptoms in subjects with idiopathic Parkinson’s disease have been studied.
U kasnijem otvorenom isitivanju (SP824), multicentričnom, multinacionalnom ispitivanju ispitivana je podnošljivost zamjene ropinirola, pramipeksola ili kabergolina s transdermalnim flasterom rotigotina preko noći i njegov učinak na simptome u ispitanika s idiopatskom Parkinsonovom bolesti.
In a subsequent open-label study (SP824), a multicenter, multinational study, the tolerability of overnight switching from ropinirole, pramipexole or cabergoline to rotigotine transdermal patch and its effect on symptoms in subjects with idiopathic Parkinson’s disease have been studied.
U kasnijem otvorenom ispitivanju (SP824), multicentričnom, multinacionalnom ispitivanju ispitivana je podnošljivost zamjene ropinirola, pramipeksola ili kabergolina s transdermalnim flasterom rotigotina preko noći i njegov učinak na simptome u ispitanika s idiopatskom Parkinsonovom bolesti.
In a subsequent study, 217 patients who were treatment- naïve to PDE5 inhibitors were randomized to CIALIS 5 mg once a day vs. placebo.
U sljedećem je ispitivanju 217 bolesnika koji prethodno nisu bili liječeni inhibitorima PDE5 randomizirano da primaju ili CIALIS u dozi od 5 mg jedanput na dan ili placebo.
In a subsequent study, 217 patients who were treatment-naïve to PDE5 inhibitors were randomized to CIALIS 5 mg once a day vs. placebo.
U sljedećem je ispitivanju 217 bolesnika koji prethodno nisu bili liječeni inhibitorima PDE5 randomizirano da primaju ili CIALIS u dozi od 5 mg jedanput na dan ili placebo.
In a subset of 1,008 adult patients who received 600 mg efavirenz daily in combination with PIs and/or NRTIs in controlled clinical studies, the most frequently reported adverse reactions of at least moderate severity reported in at least 5% of patients were rash (11.6%), dizziness (8.5%), nausea (8.0%), headache (5.7%) and fatigue (5.5%).
U podskupini od 1008 odraslih bolesnika koji su u kontroliranim kliničkim ispitivanjima primali efavirenz u dozi od 600 mg na dan u kombinaciji s inhibitorima proteaze i/ili NRTI-ma najčešće nuspojave koje su bile najmanje umjerene težine i prijavljene u najmanje 5% bolesnika bile su: osip (11,6%), omaglica (8,5%), mučnina (8,0%), glavobolja (5,7%) i umor (5,5%).
In a subset of 1050 patients with moderate to severe hypertension (DBP ≥100 mmHg) 32.7 - 51.8 % responded sufficiently to monotherapy of either telmisartan or amlodipine.
U podskupini od 1050 bolesnika s umjerenom do teškom hipertenzijom (DKT ≥100 mmHg) 32,7-51,8 % je reagiralo dostatno na monoterapiju, bilo telmisartanom ili amlodipinom.
In a subset of 1050 patients with moderate to severe hypertension (DBP ≥100 mmHg) 32.7 - 51.8 % responded sufficiently to monotherapy of either telmisartan or amlodipine.
U podskupini od 1050 bolesnika s umjerenom do teškom hipertenzijom (DKT ≥100 mmHg) 32,7-51,8% je reagiralo dostatno na monoterapiju, bilo telmisartanom ili amlodipinom.
In a subset of 598 men (SILGARD = 299; placebo = 299) in Protocol 020 who self-identified as having sex with men (MSM) efficacy against anal intraepithelial neoplasia (AIN grades 1/2/3) and anal cancer, and intra-anal persistent infection was evaluated.
U podskupini od 598 muškaraca (Silgard=299; placebo=299) u Protokolu 020 koji su sami označili da su imali spolne odnose sa muškarcima (MSM), bila je procijenjena djelotvornost cjepiva protiv analne intraepitelijalne neoplazije (AIN stupanj 1/2/3) i karcinoma anusa, te intraanalne perzistentne infekcije.